Kerri Kissell, MD
Endocrinology, Diabetes & Metabolism · Greenfield, INNPI 1043354483
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,355 of the $58,337 with a category attached, or 86.3%. 35 manufacturers reported payments, led by Merck at 55.0% of the total. Reporting peaked in 2019 at $38,486 and has fallen 99.6% since, to $135 in 2025. Among endocrinology, diabetes & metabolism clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $256.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$32K
- AstraZeneca$18K
- Senseonics, Incorporated$4K
- Lilly USA, LLC$2K
- Novo Nordisk$445
- Xeris Pharmaceuticals, Inc.$164
- plus $2K from 29 others
Across 1 payment — averaging $260.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi-aventis U.S. LLC$260
What the payments were for
- Speaking & faculty fees$50,35586%
- Travel & lodging$4,3267%
- Food & beverage$3,4326%
- Education$1640%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 23 | $32,062 |
| AstraZeneca | 44 | $18,153 |
| Senseonics, Incorporated | 2 | $4,010 |
| Lilly USA, LLC | 31 | $1,841 |
| Novo Nordisk | 29 | $445 |
| Xeris Pharmaceuticals, Inc. | 9 | $164 |
| Insulet Corporation | 6 | $162 |
| Abbott | 7 | $135 |
| Dexcom, Inc. | 7 | $114 |
| Corcept Therapeutics | 4 | $112 |
| Amgen | 7 | $110 |
| Novartis | 6 | $108 |
| Sanofi-aventis U.S. LLC | 6 | $102 |
| Valeritas, Inc. | 7 | $102 |
| Tandem Diabetes Care, Inc. | 3 | $73 |
| Boehringer Ingelheim | 4 | $63 |
| Mannkind Corporation | 1 | $59 |
| Ultragenyx Pharmaceutical Inc. | 3 | $53 |
| Amneal Pharmaceuticals LLC | 3 | $49 |
| Cequr Corporation | 2 | $48 |
| Bayer | 3 | $42 |
| GRT US Holding, Inc. | 3 | $36 |
| Medtronic | 2 | $33 |
| Antares Pharma, Inc. | 2 | $32 |
| Recordati_rare_diseases_inc. | 2 | $31 |
| AbbVie | 1 | $27 |
| Ascensia Diabetes Care US Inc. | 2 | $25 |
| Curium US LLC | 1 | $24 |
| Averitas Pharma Inc. | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Chiesi USA, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,337 in reported general payments places this provider in the 90th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 475 | $623,606 |
| OzempicSemaglutide | 354 | $486,080 |
| FarxigaDapagliflozin Propanediol | 413 | $436,115 |
| KorlymMifepristone | 11 | $221,870 |
| JardianceEmpagliflozin | 171 | $185,554 |
| RybelsusSemaglutide | 80 | $111,164 |
| QutenzaCapsaicin/Skin Cleanser | 30 | $102,851 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 99 | $95,356 |
| TrulicityDulaglutide | 65 | $88,750 |
| JanumetSitagliptin Phos/Metformin Hcl | 65 | $82,697 |
| JanuviaSitagliptin Phosphate | 79 | $70,532 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 194 | $26,401 |
| DapagliflozinDapagliflozin Propanediol | 31 | $24,607 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $22,459 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 19 | $21,352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi, Insulin Lispro | $1,841 | $737,207632 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $445 | $617,196491 claims |
| AstraZenecaFarxiga | $18,153 | $436,115413 claims |
| Corcept TherapeuticsKorlym | $112 | $221,87011 claims |
| Boehringer IngelheimJardiance | $63 | $185,554171 claims |
| MerckJanumet, Januvia, Janumet Xr | $32,062 | $172,561163 claims |
| GRT US Holding, Inc.Qutenza | $36 | $102,85130 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $49 | $5,320611 claims |
| AbbVieSynthroid | $27 | $5,07972 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Greenfield
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
- Dona GrayLafayette$92K
- Michael EconsIndianapolis$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.